CME Presentations

Tenosynovial Giant Cell Tumor: New Systemic Treatment Options to Address Unmet Needs - Part 1


Presentations


Speakers

  • John H. Healey, MD

    John H. Healey, MD

    John H. Healey, MD

    Chief, Orthopaedic Surgery

    John H. Healey, MD, is chief, Orthopaedic Service, and the Stephen McDermott Chair in Surgery at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Dr Healey in an orthopaedic surgeon specializing in caring for people with sarcomas and noncancerous tumors of the bones and soft tissue. He holds special interest in treating childhood bone cancers, such as osteosarcoma and Ewing sarcoma, and has expertise in removing tumors while preserving limbs. Dr Healey has maintained a funded research laboratory for 30 years to define the genetic causes of sarcomas and enhance drug delivery to tumors, has developed new surgical implants, holds multiple devise patents and has authored over 450 peer-reviewed scientific manuscripts and chapters.
  • William D. Tap, MD

    William D. Tap, MD

    William D. Tap, MD

    Chief, Sarcoma Medical Oncology Service

    William D. Tap, MD, is the chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Dr Tap has extensive experience in translational medicine and is currently in charge of the clinical, basic science, and translational aspects of the Sarcoma Medical Oncology Program at MSKCC. He received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania, completed his internal medicine residency at the Vanderbilt University Medical Center in Nashville, Tennessee, and a fellowship in hematology and medical oncology at the UCLA Medical Center in Los Angeles, California. Dr Tap also has a tremendous interest in Global Health Initiatives; specifically, in effecting health disparity in underserved areas of the world.

CME Information

Tenosynovial Giant Cell Tumor: New Approaches to Enhance Patient’s Functionality and Quality of Life


Global LogoPQH Logo

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Discuss the signs and symptoms of localized and diffuse types of TGCT, as well as appropriate tests to confirm a diagnosis
  • Identify patients with TGCT who are likely versus not likely to benefit from surgery
  • Describe the mechanism of action, benefits and adverse events of new and emerging pharmacologic treatment options for TGCT patients who are symptomatic and not candidates for surgery

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Thursday, October 24, 2019 from 11:00am – 12:00pm ET.

TARGET AUDIENCE

The educational design of this activity addresses the needs of oncologists, orthopedic surgeons, radiologists, sports medicine physicians, and other HCPs involved in the identification and management/treatment of patients with TGCT, including NPs, PAs, and nurses.

METHOD OF PARTICIPATION

Up until recently, the standard of care for tenosynovial giant cell tumor (TGCT) was surgery. However, often, surgery is technically challenging and fails to resolve pain and improve disability in those who are affected. The findings that TGCT is driven by CSF1 overexpression in neoplastic synovial cells have led scientist to investigate systemic treatment approaches. Recently, the US Food and Drug Administration approved one such agent, pexidartinib. The availability of systemic agents can drastically change the care of patients with this debilitating condition and who are not candidates for surgery. The standard of care of TGCT patients is changing, requiring that clinicians keep up to date with the most current and emerging evidence-based therapies, and become more knowledgeable about the signs and symptoms of the condition.

To ensure that participants benefit from the latest information on the management of TGCT, the timing of this activity series is aligned with the Connective Tissue Oncology Society (CTOS) annual meeting, the Musculoskeletal Tumor Society (MTS) annual meeting, and the National Organization for Rare Disorders’ (NORD) Rare Diseases and Orphan Products Breakthrough Summit. This first CME session will help on defining the type and prevalence of TGCT, the risks inherent to surgery and new and emerging options. A patient with TCGT will describe his journey through care from his experience with diagnostic delays, referral, and quality of life.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
John H. Healey, MD Chief, Orthopaedic Surgery Memorial Sloan Kettering Cancer Center To be disclosed prior to the presentation.
William D. Tap, MD Chief, Sarcoma Medical Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center Consultant/Independent Contractor: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis, Plexxikon Pharmaceuticals
Honoraria: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis
Advisory Board: Adaptimmune, Agios Pharmaceuticals, Blueprint, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Loxo, NannoCarrier, Novartis, Plexxikon Pharmaceuticals
Stock Shareholder: Atropos Therapeutics, Certis Oncology Solutions
Other/Royalty: Companion Diagnostics for CDK4 inhibitors
Kristen Neuhaus Patient Presenter To be disclosed prior to the presentation.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Andrea Funk Nothing to disclose
Ashley Cann Nothing to disclose
Laura Engles-Horton Nothing to disclose
Alissa Yost Nothing to disclose

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.